



SUVEN Life Sciences Ltd

Communication to investors **September 2019**

14-Nov-19

2019-20 Q2 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

		Q2-FY20 vs Q2-FY19	FY 20 YoY (6 months)
Growth in revenue		191.23%	62.86%
Growth in PAT		302.91%	128.21%
Growth in EBIDTA		274.57%	114.83%
Growth in Pre-R&D EBIDTA		201.43%	88.43%
Increase in R&D Costs		18.38%	-2.15%
R&D to sales		6.49%	5.76%







MAJOR PROFITABILITY RATIOS

	Q2 Sep 19	FY20 – Half Year
PAT to Income	25.83%	26.86%
EBIDTA to Income	41.49%	43.40%
Cash Flow to Income	27.82%	29.17%
Pre-R&D EBITDA to Income	46.73%	49.17%




Q2 to Q1 COMPARISON





REVENUE COMPARISON




14-Nov-19

2019-20 Q2 results



PAT COMPARISON



14-Nov-19

2019-20 Q2 results




EBIDTA COMPARISON





R & D – EXPENDITURE





PRE-R&D EBIDTA





PRE-R&D CASHFLOW





FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2019-20 Q2	2019-20 Q1	Growth %	2018-19 Q2	Growth %	2019-20 HY	2018-19 HY	Growth %
Income	2,799.00	2,019.93	38.57%	961.08	191.23%	4,818.93	2,958.98	62.86%
Pre-R&D EBITDA	1,307.84	1,061.41	23.22%	433.88	201.43%	2,369.25	1,257.36	88.43%
Pre-R&D EBITDA Margin	46.73%	52.55%		45.15%		49.17%	42.49%	
EBITDA	1,161.20	930.39	24.81%	310.01	274.57%	2,091.59	973.60	114.83%
EBITDA Margin	41.49%	46.06%		32.26%		43.40%	32.90%	
EBIT	1,104.95	874.55	26.34%	253.71	335.51%	1,979.49	861.53	129.77%
EBIT Margin	39.48%	43.30%		26.40%		41.08%	29.12%	
Financing costs	18.54	13.08		5.91		31.62	16.59	
Taxes	363.56	290.04		68.40		653.60	277.81	
Net Profit after tax	722.85	571.43	26.50%	179.41	302.91%	1,294.28	567.13	128.21%
NP Margin	25.83%	28.29%		18.67%		26.86%	19.17%	
EPS (basic & diluted not annualised)	5.68	4.49		1.41		10.17	4.47	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	55.91	55.50		55.61		111.41	110.69	
R&D expenses	146.64	131.01	11.93%	123.87	18.38%	277.66	283.76	-2.15%

14-Nov-19

2019-20 Q2 results

News Release



- During the period Suven secures 13 product patents covering Australia, Canada, Europe, Eurasia, India, Japan, South Korea, South Africa, Sri Lanka and USA
- Updates on CRAMS projects: Total – 117; Phase 1 – 78, Phase 2 – 34, Phase 3 – 1 and commercial – 4.
- Enrolled first patient in Phase 2 study for SUVN-G3031, conducted in USA for the treatment of Narcolepsy associated with or without Cataplexy.
- Suven completed Phase 2A, POC study for SUVN-502, conducted in USA indicated for moderate Alzheimer's. Since the data lock has occurred, the out-come of the study is expected within 3 weeks and scheduled to present during CTAD 2019 - Alzheimer Congress at San Diego, USA held on December 4-7, 2019.